arrow_back Back Filing freshness 10-Q Q1 FY2027 SEC EDGAR

PharmaCyte Biotech, Inc.

PMCB
$0.45 0.00 (-0.24%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
65 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

PharmaCyte Biotech, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $4.8M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -2.9%
FCF / Share $-0.07
Trailing P/E
Price / Book 0.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

65-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.08M
↑ +39.2%
FCF / Share Free cash flow per share
$-0.07
↑ +75.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
10
Cash Quality
28

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 65 quarters